The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss.
Jefferies Initiates Coverage On Aerovate Therapeutics with Buy Rating, Announces Price Target of $21
Jefferies analyst Eun Yang initiates coverage on Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and announces Price Target of $21.
